TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04353297

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EEG-based BCI system for (hand) Motor Imagery training
Description: The Promotoer is an all-in-one BCI-supported motor imagery (MI) training station, equipped with a computer, a commercial wireless Electroencephalography (EEG)/ Electromyography (EMG) system, a screen for therapist feedback (EEG and EMG activity monitoring) and screen for the real-time ecological feedback to patient - a custom software program that provides a for (personalized) visual representation of the patient's own hands. As such, this software allows the therapists to create an artificial reproduction of a given patient's hand/forearm by adjusting a digitally created image in shape, size, skin colour and orientation to match as much as possible the real patient hand/forearm. Training consists of the MI tasks only of the affected hand, grasping or finger extension in separate runs. The trial length will include a constant baseline period of 4 sec and a task period of maximally 10 sec for BCI intervention group. Each training session will consist of 4 runs (20 trials each).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Motor Imagery training
Description: Training consists of MI tasks only of the affected hand, grasping or finger extension in separate runs. MI training will be delivered without BCI support (ie., the Promotoer system will not provide real-time feedback of MI performance; hand/forearm visual representation will remain standstill) with a dose/setting regimen equivalent to EXP intervention. The trial length will include a constant baseline period of 4 sec and a task period of maximally 4 sec. Each training session will consist of 4 runs (20 trials each).
Study: NCT05485571

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: derma pen
Description: Group 1: Taking aseptic condition, 15 Patients were subjected to therapy with microneedling, patient will take session weekly for 12 weeks.~Group 2: Taking aseptic condition, 15 patients were subjected to combined therapy with Microneedling and methotrexate After microneedling we applied methotrexate topically (25mg/ml) at dose 0.02ml/cm2 , A maximum of 0.1-0.2ml (2.5-5 mg) on the affected areas and rub it gently then Microneedling again, patient will take session weekly for 12 weeks

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: derma pen
Description: Group 1: Taking aseptic condition, 15 Patients were subjected to therapy with microneedling, patient will take session weekly for 12 weeks.~Group 2: Taking aseptic condition, 15 patients were subjected to combined therapy with Microneedling and methotrexate After microneedling we applied methotrexate topically (25mg/ml) at dose 0.02ml/cm2 , A maximum of 0.1-0.2ml (2.5-5 mg) on the affected areas and rub it gently then Microneedling again, patient will take session weekly for 12 weeks
Study: NCT05903820

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: Oral progesterone capsules 100mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Oral progesterone capsules 100mg/day
Study: NCT06364046

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Drug-eluting beads bronchial arterial chemoembolization
Description: Drug-eluting beads bronchial arterial chemoembolization generally uses platinum-containing two-drug chemotherapy platinum (cisplatin, carboplatin, nedaplatin) combined treatment, and drug-loaded microspheres are loaded with irinotecan. The dose of chemotherapy drugs is set to 75mg/m2 of platinum, and the dose of chemotherapy through catheter infusion is reduced by 25%. The dose of drug-loaded drugs is irinotecan 80mg/ m2. Chemotherapy was perfused first, followed by embolization with drug-loaded microspheres, until the blood flow in the artery supplying the tumor slowed down and approached stagnation. The number of DEB-BACE treatments is determined by the investigator, and is given as needed according to the patient's condition, usually 1-2 times, with an interval of 28±10 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab
Description: Programmed cell death protein 1 inhibitor fixation was treated with serplulimab (Fuhong Hanlin Co., LTD.). It is administered by intravenous infusion, and the recommended dose is 200 mg, given once every 21 days. The medication will last for two years until disease progression or intolerable toxicity occurs. During immunotherapy, immunosuppressive agents will not be replaced and the dose will not be adjusted.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Serplulimab
Description: Programmed cell death protein 1 inhibitor fixation was treated with serplulimab (Fuhong Hanlin Co., LTD.). It is administered by intravenous infusion, and the recommended dose is 200 mg, given once every 21 days. The medication will last for two years until disease progression or intolerable toxicity occurs. During immunotherapy, immunosuppressive agents will not be replaced and the dose will not be adjusted.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous chemotherapy
Description: Intravenous chemotherapy with irinotecan 65mg/m2 on day 1 and day 8, given once every 21 days
Study: NCT05937022

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental Transcranial Direct Current Stimulation (tDCS)
Description: This study will deliver tDCS sessions for ten sessions completed within two weeks. Consecutive tDCS sessions are separated by at least 24 hours. Participants assigned to one of the two experimental groups will receive 20 minutes of active stimulation with a 2mA intensity over the corresponding brain regions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental Transcranial Direct Current Stimulation (tDCS)
Description: This study will deliver tDCS sessions for ten sessions completed within two weeks. Consecutive tDCS sessions are separated by at least 24 hours. Participants assigned to one of the two experimental groups will receive 20 minutes of active stimulation with a 2mA intensity over the corresponding brain regions.
Study: NCT06080269

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional therapy alone
Description: Participants in the control group will receive only conventional therapy
Study: NCT05937022

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation (tDCS)
Description: This study will deliver tDCS sessions for ten sessions completed within two weeks. Consecutive tDCS sessions are separated by at least 24 hours. Participants assigned to the sham control group will receive 30 seconds of active stimulation over brain regions identical to either the left DLPFC or the right VLPFC experimental tDCS group.
Study: NCT04598282

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prokera Slim
Description: Placement of an Adjunctive Cryopreserved Amniotic Membrane Treatment.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Standard of care includes epithelial debridement of all dendrites via Weck-Cel Cellulose sponge, topical prophylactic antibiotics (e.g., Ocuflox QID for one week) and oral acyclovir (400 mg 5x/day for 10 days for primary cases but tapered to 2x/day for 3 months for recurrent cases based on investigator's discretion).
Study: NCT05156229

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDK-003
Description: CDK-003 administered subcutaneously
Study: NCT06332794

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KOKU4PD
Description: Exercise at home using the KOKU app for 4 weeks.
Study: NCT05604729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Botulinum Neurotoxin type A

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution
Study: NCT05371210

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SAIF
Description: Participants interacted with SAIF system at least 2-3 times per week; each session took up to 20 minutes.
Study: NCT06540040

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aquacel Ag
Description: Aquacel Ag is a Hydrofibre wound dressing composed of non-woven sodium carboxymethylcellulose fibers integrated with ionic silver. It is designed to provide a moist wound environment and has antimicrobial properties to help reduce the risk of infection. The dressing will be applied post-operatively and changed according to a standardized protocol.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OPSITE
Description: OPSITE is a transparent waterproof dressing with a high Moisture Vapour Transmission Rate. It is intended to provide a protective barrier while allowing moisture vapor to escape, maintaining an optimal wound healing environment. The dressing will be applied post-operatively and changed according to a standardized protocol.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MEPILEX POST OP BORDER
Description: MEPILEX POST OP BORDER is a 4-layer foam dressing designed with flex technology for superior absorption and conformability. It helps manage exudate and protects the wound site. The dressing will be applied post-operatively and changed according to a standardized protocol.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Dressing
Description: Traditional dressing involves the use of gauze pieces, surgical pads, and porous paper adhesive strips. This type of dressing is commonly used in post-operative care to absorb exudate and protect the wound site. The dressing will be applied post-operatively and changed according to a standardized protocol.
Study: NCT05267639

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Power Knee
Description: Newest version of the commercially-available Power Knee developed by Ossur.
Study: NCT05409924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATR-258
Description: Single Ascending Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATR-258
Description: Multiple Ascending Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATR-258
Description: Repeat Dose
Study: NCT06262087

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Change of direction training
Description: The experimental group is implemented FIFA 11+ program combined with COD training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FIFA 11+ program
Description: The experimental group is implemented FIFA 11+ program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FIFA 11+ program
Description: The experimental group is implemented FIFA 11+ program.
Study: NCT04950608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Oral, single administration, dosage 25 mg orally

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: The treatment regimen consists of a single administration of psilocybin orally combined with a supportive psychotherapy including 2 preparation sessions and 2 integration sessions
Study: NCT04776148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: IV infusion
Study: NCT05900739

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increase of fruit and vegetable consumption
Description: Week 1 Presentation of the program. Healthy eating Week 2 Fruit and vegetable: nutritional value, types, seasonality, benefits for health Week 3 Shopping Fruit and vegetable: tips, places, conservation methods Week 4 Healthy menu planning with My Plate Week 5 How to cook Fruit and Vegetable avoiding food waste Week 6 Healthy snacks using Fruit and vegetable Week 7 Batch cooking

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increase of fruit and vegetable consumption
Description: Week 1 Presentation of the program. Healthy eating Week 2 Fruit and vegetable: nutritional value, types, seasonality, benefits for health Week 3 Shopping Fruit and vegetable: tips, places, conservation methods Week 4 Healthy menu planning with My Plate Week 5 How to cook Fruit and Vegetable avoiding food waste Week 6 Healthy snacks using Fruit and vegetable Week 7 Batch cooking

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increase of fruit and vegetable consumption
Description: Week 1 Presentation of the program. Healthy eating Week 2 Fruit and vegetable: nutritional value, types, seasonality, benefits for health Week 3 Shopping Fruit and vegetable: tips, places, conservation methods Week 4 Healthy menu planning with My Plate Week 5 How to cook Fruit and Vegetable avoiding food waste Week 6 Healthy snacks using Fruit and vegetable Week 7 Batch cooking
Study: NCT04776148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenvatinib
Description: oral capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: regorafenib
Description: oral tablet
Study: NCT05067556

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy for chronic pain (ACT-CP)
Description: Delivered virtually via Zoom or via telephone on an individual level; 30-minute sessions led by a trained psychologist and occur weekly for 6 weeks.
Study: NCT05861518

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: In the hypnosis group, patients were given hypnosis sessions of approximately 30 minutes each, in groups of three, once a week. In this way, session standardization was achieved. Arm catalepsy was suggested in all patients. The first session was used as hypnosis induction, progressive muscular relaxation and introduction to hypnosis. In the second session, in addition to the first session, self-hypnosis training was given. The second session was applied as the same 3rd session. In these patients, in addition to analgesia suggestions, the feeling of worthlessness was especially studied with the recommendation of a psychiatrist.
Study: NCT05966545

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pars plana vitrectomy and intraocular foreign body removal
Description: removal of vitreous body and attachment to foreign body then extraction of foreign body

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pars plana vitrectomy and intraocular foreign body removal
Description: removal of vitreous body and attachment to foreign body then extraction of foreign body
Study: NCT06585332

Intervention type: OTHER
Intervention: Assessment of respiratory paramenters (Maximal inspiratory pressure, maximal expiratory pressure, and voluntary peak cough flow))
Description: The voluntary peak cough flow is measured using a pneumotachograph (BTL cardiopoint Spiro, BTL industries), which meets the recommendations of the American Thoracic Society and the European Respiratory Society for range and accuracy in forced expiratory maneuvers.~Maximal expiratory and inspiratory pressures assessments were performed using a flanged rubber mouthpiece connected to a pressure manometer (Micro RPM, Vyaire Medical). Assessments are conducted according to the statements on respiratory muscle testing of the American Thoracic Society and the European Respiratory Society.~Hand grip strength Grip strength is measured using DHD-1 digital hand dynamometer (SAEHAN®,Seahan Corporation), assessment follows recommendation of The American Society of Hand Therapists.
Study: NCT06585345

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD7 CAR-T cell
Description: Split intravenous infusion of CD7 CAR-T cells \[dose escalating infusion of (1-100)x10\^6 CD7 CAR-T cells/kg\]
Study: NCT06584994

Intervention type: OTHER
Intervention: sample collection
Description: Collection of blood, skin, semen, urine and/or saliva samples. Access to previously collected tissue samples (if applicable).

Intervention type: OTHER
Intervention: sample collection
Description: Collection of blood, skin, semen, urine and/or saliva samples. Access to previously collected tissue samples (if applicable).

Intervention type: OTHER
Intervention: sample collection
Description: Collection of blood, skin, semen, urine and/or saliva samples. Access to previously collected tissue samples (if applicable).
Study: NCT06091813

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Counseling
Description: Dietitian-led nutrition coaching via 5 Telenutrition visits, utilizing the Academy of Nutrition and Dietetics' Nutrition Care Process.
Study: NCT05552235

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Elbow SOFT 300
Description: 15 patients will be included in this group and will used the medical device ElbowSOFT 300 during sport practice (at least 2 sport sessions per week), for 6 weeks.

Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: 15 patients will be included in this control group and will performed their sport sessions as usual (without the medical device), for at least 2 sport sessions per week during 6 weeks.
Study: NCT06156761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone hydrochloride liposome
Description: Drug: Mitoxantrone hydrochloride liposome (16 mg/m\^2, 18 mg/m\^2, 20 mg/m\^2 and 22 mg/m\^2) will be administered by intravenous infusion on day 1 in a 3-week treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine (1000 mg/m\^2) will be administered orally in a 3-week treatment cycle, twice a day from day 1 to day 14 of each cycle.
Study: NCT04776148

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAS-102 (trifluridine and tipiracil)
Description: oral tablet
Study: NCT06100614

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Presepsin
Description: Umbilical cord blood or blood from the first routine venous puncture within four hours after birth will be used for presepsin determination. Presepsin measurement can be performed in 100 μl plasma with PATHFAST™ Presepsin which is a rapid chemiluminescent enzyme immunoassay (Mitsubishi Chemical Medience corporation, Tokyo, Japan) with results available within 15 minutes.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Standard care according to the Dutch EOS guideline
Study: NCT06156761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone hydrochloride liposome
Description: Mitoxantrone hydrochloride liposome (16 mg/m\^2, 18 mg/m\^2, 20 mg/m\^2 and 22 mg/m\^2) will be administered by intravenous infusion on day 1 in a 4-week treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine (825 mg/m\^2) will be administered orally in a 4-week treatment cycle, twice a day from day 1 to day 21 of each cycle.
Study: NCT05555121

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone Effervescent Vaginal Tablet
Description: On the day of Frozen Embryo Transfer (FET), women will have a blood test to determine progesterone levels. Depending on the result of progesterone level, the participant will be assigned to either the Endometrin 100 mg TID dose or the Endometrin 200 mg TID dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone Effervescent Vaginal Tablet
Description: On the day of Frozen Embryo Transfer (FET), women will have a blood test to determine progesterone levels. Depending on the result of progesterone level, the participant will be assigned to either the Endometrin 100 mg TID dose or the Endometrin 200 mg TID dose
Study: NCT06280066

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Program Based on Strengthening the Psychological Resilience of Children Diagnosed with Cystic Fibrosis and Their Mothers
Description: The content of the Intervention Program Based on Strengthening the Psychological Resilience of Children Diagnosed with Cystic Fibrosis and Their Mothers will include the Psychological Resiliency Program for Children and Adolescents developed by Akar (2018), laughter yoga, meditation, breathing exercises and therapeutic story sessions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Program Based on Strengthening the Psychological Resilience of Children Diagnosed with Cystic Fibrosis and Their Mothers
Description: The content of the Intervention Program Based on Strengthening the Psychological Resilience of Children Diagnosed with Cystic Fibrosis and Their Mothers will include the Psychological Resiliency Program for Children and Adolescents developed by Akar (2018), laughter yoga, meditation, breathing exercises and therapeutic story sessions.
Study: NCT05336318

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer support
Description: patients were supported by a mentor
Study: NCT04589065

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Selective Cytopheretic Device
Description: SCD therapy will take place for 4 hours on day 1, 3, and 5 while on hemodialysis treatment. Participants will be continue to be followed until 30 days after the last SCD treatment.
Study: NCT04898010

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Selective Cytopheretic Device
Description: The Selective Cytopheretic Device (SCD) treatment will be delivered using a two-cartridge system using a type of dialysis equipment commonly used for conventional hemodialysis therapy. The SCD cartridge will be added immediately post-hemofilter to the circuit of a standard hemodialysis system, and treatment will be delivered for 24 hours. Blood exchange will occur using a dialysis catheter.
Study: NCT06387784

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot juice
Description: In the morning, pregnant women with pre-eclampsia will consume a single dose of 70 ml of nitrate-rich beetroot juice containing 400 mg of nitrate. Participants will be monitored to assess the acute effects of nitrate intake for 6 hours.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot juice
Description: In the morning, pregnant women with pre-eclampsia will consume a single dose of 70 ml of nitrate-rich beetroot juice containing 400 mg of nitrate. Participants will be monitored to assess the acute effects of nitrate intake for 6 hours.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo juice
Description: In the morning, pregnant women with pre-eclampsia will consume 70 ml of a placebo juice. The placebo juice will be similar in appearance and taste to the nitrate-rich beetroot juice. Participants will be monitored to compare the acute effects of beetroot juice with the placebo intake for 6 hours.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo juice
Description: In the morning, pregnant women with pre-eclampsia will consume 70 ml of a placebo juice. The placebo juice will be similar in appearance and taste to the nitrate-rich beetroot juice. Participants will be monitored to compare the acute effects of beetroot juice with the placebo intake for 6 hours.